ASH 2020 | MRD-oriented trials for patients with relapsed T-ALL
Josep-Maria Ribera, MD, PhD, Germans Trias i Pujol University Hospital, Barcelona, Spain, discusses the results of a retrospective analysis investigating the outcomes of patients with relapsed T-cell acute lymphoblastic leukemia (T-ALL) treated in two recent measurable residual disease (MRD)-oriented trials, the ALL-AR-03 (NCT00853008) trial and the ALL-HR-11 (NCT01540812) trial. Analysis showed that adults with relapsed T-ALL had poor outcomes, with complete remission to first salvage therapy of 44% and a median overall survival of 6 months. This study highlights the need for novel therapies for the effective treatment of T-ALL. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Josep-Maria Ribera, has been a speaker, participated in advisory boards and received honoraria from Pfizer, AMGEN, Shire and Ariad; has participated in clinical trials with Pfizer, AMGEN and Ariad; and has received research support from AMGEN.
